Lior Alkalay

Lior Alkalay

InvestorPlace Contributor

Lior is a consummate professional; a passionate analyst and economist with comprehensive experience within the financial services sector. With nearly 10 years of experience in trading and investment, Lior has provided his clients with crisp, clear and thorough analysis. Before becoming an independent analyst, he was employed for several years as the director of sell-side research at a leading international broker.

Lior specializes in mid- to long-range stock and ETF analyses using an out-of-the-box investment approach. That approach includes top-down analysis to identify the most attractive sectors, and then he balances it with cherry-picking to find the best opportunities.

Recent Articles

3 Big Pharma Stocks to Buy, 3 to Avoid

By Lior Alkalay, InvestorPlace Contributor

Big Pharma stocks are under pressure as regulation threatens to curb drug prices and tax driven mergers are intercepted by the treasury.

Pandora Media Inc: It’s Make-or-Break Time for P Stock

By Lior Alkalay, InvestorPlace Contributor

If Pandora (P) cuts back on the royalties it pays, the stock could rally. But if it fails, Pandora stock will plunge even lower.

American Airlines Group Inc: Why You Should Avoid AAL Stock

By Lior Alkalay, InvestorPlace Contributor

American Airlines has a poor earnings record, failing to cut costs in bad times and grow in the good time. Simply put, AAL stock is not worth the risk.

Why You WANT Alphabet Inc (GOOGL) to Get Smaller

By Lior Alkalay, InvestorPlace Contributor

GOOGL Stock needs to scale back unprofitable investments such as Boston Dynamics, if it hopes to maintain its bullish price momentum.

MetLife Inc Is a Cherry Everyone Is Missing (MET)

By Lior Alkalay, InvestorPlace Contributor

Metlife stock has a solid intrinsic value and yet is priced cheaply just because MET is in the insurance business. This distortion will not last long.

Load More